Detalles de la búsqueda
1.
Circulating haematopoietic stem cells and long-term outcomes of COVID-19.
Eur J Clin Invest
; 54(4): e14150, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38088242
2.
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
Diabetes Obes Metab
; 26(6): 2390-2400, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38477183
3.
Multisensor Integrated Platform Based on MEMS Charge Variation Sensing Technology for Biopotential Acquisition.
Sensors (Basel)
; 24(5)2024 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38475089
4.
Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cells.
Diabetologia
; 66(12): 2346-2355, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37712954
5.
Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Diabetes Obes Metab
; 25(10): 2963-2969, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37402697
6.
A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease.
Diabetologia
; 65(9): 1555-1568, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35708762
7.
Physicians' misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes.
Cardiovasc Diabetol
; 21(1): 57, 2022 04 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35473579
8.
Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis.
Cardiovasc Diabetol
; 21(1): 159, 2022 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35996111
9.
Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care.
Cardiovasc Diabetol
; 21(1): 274, 2022 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36494815
10.
Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors.
Diabetes Obes Metab
; 24(2): 177-186, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34747123
11.
Urine-Derived Epithelial Cells as a New Model to Study Renal Metabolic Phenotypes of Patients with Glycogen Storage Disease 1a.
Int J Mol Sci
; 24(1)2022 Dec 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36613675
12.
Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial.
Diabetologia
; 64(10): 2334-2344, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34368894
13.
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Cardiovasc Diabetol
; 20(1): 39, 2021 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33573667
14.
Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.
Cardiovasc Diabetol
; 20(1): 222, 2021 11 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774054
15.
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Cardiovasc Diabetol
; 20(1): 144, 2021 07 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34271920
16.
PAR-4/Ca2+-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes.
Cardiovasc Diabetol
; 20(1): 77, 2021 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33812377
17.
Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
Diabetes Metab Res Rev
; 37(1): e3353, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32453482
18.
Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives.
Rev Endocr Metab Disord
; 22(2): 217-240, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33755854
19.
Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.
Nephrol Dial Transplant
; 36(12): 2263-2273, 2021 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33367744
20.
Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society.
Nutr Metab Cardiovasc Dis
; 31(12): 3257-3270, 2021 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34627692